Light therapy is gaining immense popularity for treating a variety of diseases. According to Coherent Market Insights, the global light therapy industry is set to grow at a CAGR of 5.2% during the forecast period. The target industry value will likely cross US$ 1410.9 million by the end of 2030.
Koninklijke Philips N.V., PhotonMD, Inc., Verilux, Inc., BioPhotas, TheraLight LLC, Beurer GmbH, Johnson & Johnson, and Zepter International are few light therapy device manufacturers and suppliers. These players are constantly innovating to develop advanced phototherapy devices.
Top players are initiating new trials to demonstrate the effectiveness of light therapy in treating various diseases. Acquisitions, partnerships, and collaborations are also becoming common in the industry.
In June 2024, TheraLight LLC, a global leader in light therapy, launched TheraLight 360+ full body photobiomodulation therapy bed. The new bed brings additional power to the combined wavelengths of 810nm, 633nm, 850nm, and 940nm.
TheraLight 360+ has 25% more power. It features a more robust shell casing and enhanced tablet control and is designed to improve the patient experience and provide better therapeutic outcomes.
In August 2024, TheraLight also received a new patent for its photobiomodulation system from USPTO. This is set to introduce groundbreaking advancements in light therapy technology.
In March 2025, PhotoPharmics, a leader in specialized phototherapy for neurodegenerative diseases, started latest phototherapy trial for Parkinson’s disease. The new trial is intended to assess the efficacy of the company’s breakthrough phototherapy device, Celeste to improve overall function and quality of life in Parkinson’s disease.
